Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Change in Cash (2016 - 2025)

Historic Change in Cash for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to -$56.7 million.

  • Prestige Consumer Healthcare's Change in Cash fell 841846.85% to -$56.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.5 million, marking a year-over-year increase of 19025.19%. This contributed to the annual value of $51.4 million for FY2025, which is 52774.54% up from last year.
  • Latest data reveals that Prestige Consumer Healthcare reported Change in Cash of -$56.7 million as of Q4 2025, which was down 841846.85% from -$20.4 million recorded in Q3 2025.
  • Prestige Consumer Healthcare's 5-year Change in Cash high stood at $131.3 million for Q2 2021, and its period low was -$120.8 million during Q3 2021.
  • In the last 5 years, Prestige Consumer Healthcare's Change in Cash had a median value of $1.4 million in 2023 and averaged $13500.0.
  • As far as peak fluctuations go, Prestige Consumer Healthcare's Change in Cash soared by 45666.91% in 2021, and later crashed by 841846.85% in 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Change in Cash (Quarter) stood at -$21.8 million in 2021, then soared by 301.45% to $43.9 million in 2022, then tumbled by 91.92% to $3.5 million in 2023, then crashed by 118.77% to -$666000.0 in 2024, then plummeted by 8418.47% to -$56.7 million in 2025.
  • Its last three reported values are -$56.7 million in Q4 2025, -$20.4 million for Q3 2025, and $41.6 million during Q2 2025.